Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Tomomi Matsuura  (Matsuura T) 1 Article
Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Daiju Fukuda, Hotimah Masdan Salim, Masayoshi Ishida, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Toshio Matsumoto, Masataka Sata
Diabetes Metab J. 2015;39(4):342-347.   Published online July 21, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.4.342
  • 4,400 View
  • 58 Download
  • 18 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   
Background

Predictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus. The aim of this study is therefore to clarify predictive factors of the efficacy of DPP-4 inhibitors for lowering HbA1c after 12 months of treatment.

Methods

A total of 191 consecutive type 2 diabetic patients (male sex 55%, mean age, 68.3±35.8 years), who had been treated with DPP-4 inhibitors for 12 months, were enrolled in this study and evaluated retrospectively.

Results

After 12 months of DPP-4 inhibitor treatment, random blood glucose level, and HbA1c level, decreased from 167±63 to 151±49 mg/dL (P<0.01), and from 7.5%±1.3% to 6.9%±0.9% (P<0.01) respectively, without severe side effects. Multiple regression analysis showed that predictors of DPP-4 inhibitor treatment efficacy in lowering HbA1c level after 12 months were a decrease in HbA1c level after 3 months of treatment, a high baseline HbA1c level, a low baseline body mass index, and the absence of coronary artery disease.

Conclusion

Most suitable candidates for treatment with DPP-4 inhibitors are diabetics who are not obese and do not have coronary artery disease. In addition, long-term efficacy of DPP-4 inhibitors can be predicted by decrement of HbA1c after 3 months of treatment.

Citations

Citations to this article as recorded by  
  • Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
    Shiau Chin Chong, Norlela Sukor, Sarah Anne Robert, Kim Fong Ng, Nor Azmi Kamaruddin
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
    Takahiro Abe, Yasuhiro Matsubayashi, Sayaka Muragishi, Akihiro Yoshida, Hideki Suganami, Kenichi Furusawa, Kazuya Fujihara, Shiro Tanaka, Kohei Kaku, Hirohito Sone
    Journal of Diabetes Investigation.2021; 12(10): 1805.     CrossRef
  • Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study
    Makoto Ohara, Hiroe Nagaike, Tomoki Fujikawa, Yo Kohata, Maiho Ogawa, Takemasa Omachi, Risa Sasajima, Hirotoshi Chiba, Toshimasa Ara, Ayuka Sugawara, Munenori Hiromura, Michishige Terasaki, Yusaku Mori, Tomoyasu Fukui, Tsutomu Hirano, Hiroki Yokoyama, Sho
    Diabetes Research and Clinical Practice.2021; 179: 108999.     CrossRef
  • Factors associated with the glucose‐lowering efficacy of sitagliptin in Japanese patients with type 2 diabetes mellitus: Pooled analysis of Japanese clinical trials
    Naoko Tajima, Jun‐ichi Eiki, Taro Okamoto, Kotoba Okuyama, Masaru Kawashima, Samuel S Engel
    Journal of Diabetes Investigation.2020; 11(3): 640.     CrossRef
  • Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
    Alina Y. Babenko, Anna A. Mosikian, Igor E. Makarenko, Victoriya V. Leusheva, Evgeny V. Shlyakhto
    Diabetes mellitus.2018; 21(4): 241.     CrossRef
  • Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Shusuke Yagi, Ken-ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Hotimah Masdan Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Ko
    Advances in Therapy.2018; 35(1): 124.     CrossRef
  • Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis
    Yuli Cai, Tianshu Zeng, Zhongyuan Wen, Lulu Chen
    Diabetes Therapy.2018; 9(1): 177.     CrossRef
  • Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
    Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto
    Diabetes mellitus.2018; 21(5): 333.     CrossRef
  • Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials
    Guang Ning, Tushar Bandgar, Uwe Hehnke, Jisoo Lee, Juliana C. N. Chan
    Advances in Therapy.2017; 34(9): 2150.     CrossRef
  • Potential regulatory mechanisms of lncRNA in diabetes and its complications
    Shui-Dong Feng, Ji-Hua Yang, Chao Hua Yao, Si-Si Yang, Ze-Mei Zhu, Di Wu, Hong-Yan Ling, Liang Zhang
    Biochemistry and Cell Biology.2017; 95(3): 361.     CrossRef
  • Baseline Body Mass Index and the Efficacy of Hypoglycemic Treatment in Type 2 Diabetes: A Meta-Analysis
    Xiaoling Cai, Wenjia Yang, Xueying Gao, Lingli Zhou, Xueyao Han, Linong Ji, Francesco Giorgino
    PLOS ONE.2016; 11(12): e0166625.     CrossRef
  • Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis
    Xiaoling Cai, Wenjia Yang, Yifei Chen, Xueying Gao, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji
    Expert Opinion on Pharmacotherapy.2016; 17(12): 1591.     CrossRef
  • Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes
    Rose Anderson, Jennifer Hayes, Jeffrey W. Stephens
    Expert Opinion on Drug Metabolism & Toxicology.2016; 12(4): 467.     CrossRef
  • Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2015;39:342-7)
    Ye An Kim
    Diabetes & Metabolism Journal.2015; 39(5): 444.     CrossRef
  • Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2015;39:342-7)
    Shusuke Yagi, Ken-ichi Aihara, Masataka Sata
    Diabetes & Metabolism Journal.2015; 39(5): 446.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer